SpringerPlus

Table 1 Percentage (%) of cells with chromosome aberrations (CAs), %MN, percent of micronucleated binuclear cells (%MNBN) and frequency of SCE in human peripheral blood lymphocytes treated with PMX + CFX for 24- and 48-h treatment periods

From: In vitro genotoxicity and cytotoxicity of a particular combination of pemetrexed and cefixime in human peripheral blood lymphocytes

	Treatment
Test substance	Time (h)	Concentration (μg/mL)	% Cells with CAs ± S.E.	MN ± S.E. (%)	%MNBN ± S.E.	SCE/Cell ± S.E.	Min-Max SCE
Control	-	-	0.50 ± 0.28	0.30 ± 0.09	0.30 ± 0.09	5.56 ± 0.16	1-12
DMSO	24	9 μL	1.75 ± 0.75	0.17 ± 0.07	0.17 ± 0.07	4.54 ± 0.68	1-13
MMC	24	0.25	9.25 ± 1.03	1.72 ± 0.28	1.72 ± 0.28	21.54 ± 1.39	6-47
PMX + CFX	24	12.5 + 450	2.00 ± 0.40 c₃	0.22 ± 0.02 c₃	0.22 ± 0.02 c₃	5.65 ± 0.77 c₃	1-33
		25 + 800	3.25±0.85 a₁c₃	0.12±0.06 c₃	0.10± 0.04 c₃	4.28±0.12 c₃	1-13
		37.5 + 1150	2.50±1.04 c₃	0.02±0.02 c₃	0.02±0.02 c₃	3.77±0.73 c₃	1-12
		50 + 1500	2.00±0.70 c₃	0.10±0.04 c₃	0.10±0.04 c₃	3.71±0.69 c₃	1-11
DMSO	48	9 μL	1.00 ± 0.00	0.30 ± 0.14	0.27 ± 0.12	4.11 ± 0.42	1-13
MMC	48	0.25	13.25 ± 1.54	2.90 ± 0.43	2.87 ± 0.44	41.19 ± 4.66	2-78
PMX + CFX	48	12.5 + 450	1.25 ± 0.75 c₃	0.12 ± 0.02 c₃	0.12 ± 0.02 c₃	7.27 ± 1.52 c₃	1-34
		25 + 800	1.25±0.25 c₃	0.10±0.04 c₃	0.10±0.04 c₃	3.82±0.33 c₃	1-14
		37.5 + 1150	0.75±0.47 c₃	0.12±0.04 c₃	0.12±0.04 c₃	3.28±0.26 c₃	1-9
		50 + 1500	0.50 ± 0.50 c₃	0.05±0.02 c₃	0.05±0.02 c₃	4.00±0.17 c₃	1-8

All data are expressed as mean ± S.E; n = 4.
400 cells were scored per concentration in the CA assay.
4000 cells were scored for the %MNBN.
100 cells were scored per concentration for the SCE assay.
a, significant from control; b, significant from solvent control (DMSO); c, significant from positive control (MMC). a₁b₁c₁: p < 0.05; a₂b₂c₂: p < 0.01; a₃b₃c₃: p < 0.001.

Back to article page